Officer sold ~$54K of Edwards Lifesciences
Scheduled in advanceLoading…
EW · NYSE · Health Care Equipment
Health Care Equipment company based in Irvine, California.
Last close, Oct 1, 2026
$85.19
Adjusted for splits and dividends
Last 12 months
+11.6%
S&P 500 +14.3% over the same dates
Market value
$49.1B
Last close × shares outstanding
Bets against the stock: 9.09M shares sold short (1.6% of shares outstanding), +0.7% vs the previous count, 3.1 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
11 sales
$4.54M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$6.07B
+11.5% vs the year before
Net income, fiscal 2025
$1.07B
As reported in the annual filing
Shares outstanding
576M
As of Jul 31, 2026
In fiscal 2025 the company spent $893M buying back its own shares. Cash actually paid, from its cash-flow statement.
Officer sold ~$54K of Edwards Lifesciences
Scheduled in advanceStock since the trade -6.1% · S&P 500 -0.4% · to Oct 1Traded 39 days after resultsStock within 5% of its 52-week high
15K → 15K shares held−4% of their stake
Edwards Lifesciences's SVP, Corporate Controller sold $50K of Edwards Lifesciences shares. Nobody planned it ahead of time.
Stock since the trade -5.6% · S&P 500 -0.7% · to Oct 1Traded 36 days after resultsStock 24% above its 52-week low and 5% below its high
21K → 18K shares held−13% of their stake
Edwards Lifesciences's CVP, EMEACLA sold $238K of Edwards Lifesciences shares. Nobody planned it ahead of time.
Stock since the trade -6.2% · S&P 500 -0.3% · to Oct 1Traded 34 days after resultsStock within 5% of its 52-week high
75K → 44K shares held−41% of their stake
Edwards Lifesciences's CVP, TMTT, Surgical & IHFM sold $2.79M of Edwards Lifesciences shares. Nobody planned it ahead of time.
Stock since the trade -6.2% · S&P 500 -0.3% · to Oct 1Traded 34 days after resultsStock within 5% of its 52-week high
22K → 20K shares held−6% of their stake
Edwards Lifesciences's CVP, JAPAC sold $113K of Edwards Lifesciences shares. Nobody planned it ahead of time.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Short sale volume: 44.7% of the volume reported to FINRA over the last 20 trading days was marked short, close to its 1-year average of 43.2%. FINRA daily files, to Oct 2, 2026.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock.
Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.
A securities lawsuit naming the company as a defendant was filed on Oct 14, 2024 in the U.S. District Court, C.D. California. A filing is an allegation, not a finding.
Dhimant Patel v. Edwards Lifesciences Corporation, 8:24-cv-02221Federal civil cases with nature of suit 850 (securities) filed in the last 3 years where the company is the first named defendant, from court records on CourtListener (Free Law Project). Coverage of court records is not complete, and shareholder derivative suits are not included.
8 approvals or clearances and 1 recall recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Vanguard Capital Management
Schedule 13G: passive · filed Apr 29, 2026 · 43.5M shares
BlackRock, Inc.
Schedule 13G: passive · filed Oct 17, 2025 · 44.3M shares
Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.
18 certified in FY2026 Q3, vs 29 a year earlier. 18 positions in total, median offered wage $123K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
Last 12 months, adjusted daily closes
Adjusted close went from $76.31 on Oct 1, 2025 to $85.19 on Oct 1, 2026 (+11.6%). Disclosed trades in the last 12 months: 0 insider purchases, 53 insider sales (30 under pre-arranged plans), 1 Congress purchase, 1 Congress sale.